ImmunityBio to Provide Strategic and Financial Outlook in Upcoming Call

ImmunityBio to detail 2025 guidance, ANKTIVA's 700% revenue growth, expansion to 33 countries, and upcoming Phase 2 trial results for bladder cancer.

ImmunityBio has scheduled a live conference call for Tuesday, during which management will deliver a business update and elaborate on its full-year 2025 financial guidance. The session is expected to focus heavily on the ongoing clinical progress and recent commercial traction of its therapy, ANKTIVA.

Commercial Momentum and Regulatory Expansion

A significant portion of the discussion will likely center on ANKTIVA's commercial performance. In a previous communication regarding its 2025 results, the company reported net product revenue of approximately $113 million. This figure represented a surge of roughly 700% compared to the prior year. Furthermore, the report indicated quarter-over-quarter net product revenue growth of 20%, a trend investors will be keen to see confirmed as continuing.

On the regulatory front, ImmunityBio has substantially expanded ANKTIVA's geographic footprint. The treatment is now approved in 33 countries, including the United States, the United Kingdom, the European Union, and Saudi Arabia for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. Notably, the company secured its first approval outside of bladder cancer in Saudi Arabia, where ANKTIVA, in combination with checkpoint inhibitors, is authorized for certain patients with metastatic non-small cell lung cancer. To support its European commercialization efforts, ImmunityBio has partnered with Accord Healthcare and established an Irish subsidiary.

Clinical Development Milestones and Forward Path

The upcoming update follows several key clinical achievements. In late February, ImmunityBio completed patient enrollment in a registrational Phase 2 trial. This study is evaluating ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone for a specific form of NMIBC.

Based on the outcomes of this trial, the company intends to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for this indication by the fourth quarter of 2026. Consequently, the conference call will be scrutinized for any additional details regarding the study's analysis timeline and the projected regulatory pathway.

Tuesday's call will serve to contextualize these commercial, regulatory, and clinical developments within ImmunityBio's broader business outlook and 2025 financial framework.